[Trends in therapeutic guidelines for rheumatoid arthritis].
Miyasaka
Nobuyuki
N
D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D018501:Antirheumatic Agents / Q000008:administration & dosage*; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000517:prevention & control / Q000628:therapy*; D001323:Autoantibodies / Q000097:blood; D015415:Biomarkers / Q000097:blood; D006801:Humans; D000069285:Infliximab; D008279:Magnetic Resonance Imaging; D019278:Matrix Metalloproteinase 3 / Q000097:blood; D008727:Methotrexate / Q000008:administration & dosage; D010173:Palpation; D010456:Peptides, Cyclic / Q000276:immunology; D017410:Practice Guidelines as Topic; D012074:Remission Induction; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D001323:Autoantibodies; D015415:Biomarkers; D010456:Peptides, Cyclic; D014409:Tumor Necrosis Factor-alpha; C487763:cyclic citrullinated peptide; D000069285:Infliximab; D019278:Matrix Metalloproteinase 3; D008727:Methotrexate